FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894098963> ?p ?o ?g. }

• W2894098963 endingPage "90" @default.
• W2894098963 startingPage "84" @default.
• W2894098963 abstract "What is known and objective Linezolid-induced thrombocytopenia is one of the many confounding conditions in critically ill patients. It is rare but prognostic importance of linezolid-induced thrombocytopenia in ICU population has not been well investigated. The study is to assess the incidence and risk factors of linezolid-induced thrombocytopenia in ICU patients. Methods We conducted a retrospective study with ICU patients treated with linezolid between January 2005 and December 2015 at the adult medical, surgical, emergency, and neurological ICUs at 1500-bed tertiary university medical center. Results and discussion There were 60 patients (mean age: 69.8 ± 11.9), 29 (48.3%) who developed linezolid-induced thrombocytopenia determined by the Naranjo algorithm on a case-by-case basis during the study period. The patients with linezolid-induced thrombocytopenia had a higher rate of any malignancy (41.4% vs 9.7%, P = 0.007), elevated baseline creatinine levels (median [interquartile range; IQR]: 1.7 mg/dL [0.9-2.5] vs 0.9 mg/dL [0.6-1.3]; P = 0.042), and lower baseline platelet counts (median [IQR] 160 × 109/L [128-230] vs 194 × 109/L [118-285]; P = 0.296) than patients without linezolid-induced thrombocytopenia. The patients who developed thrombocytopenia received more platelet transfusions (34.5% vs 6.5%, P = 0.009) and had higher ICU mortality rates (62.1% vs 32.3%, P = 0.037). Logistic regression analysis revealed the following significant risk factors for linezolid-induced thrombocytopenia: presence of any malignancy (odds ratio; OR [95% confidence interval; CI]: 8.667 [1.986-37.831]) and an elevated baseline serum creatinine level (OR: 1.673, CI: 1.046-2.675]). What is new and conclusion Critically ill patients with any malignancy or an elevated baseline creatinine level who were treated with linezolid in the ICU were more likely to develop thrombocytopenia. More importantly, mortality increased with patients who developed linezolid-induced thrombocytopenia compared to those did not." @default.
• W2894098963 created "2018-10-05" @default.
• W2894098963 creator A5004277197 @default.
• W2894098963 creator A5011456672 @default.
• W2894098963 creator A5030817312 @default.
• W2894098963 creator A5082469456 @default.
• W2894098963 creator A5086570504 @default.
• W2894098963 date "2018-09-22" @default.
• W2894098963 modified "2023-10-18" @default.
• W2894098963 title "Linezolid-induced thrombocytopenia increases mortality risk in intensive care unit patients, a 10 year retrospective study" @default.
• W2894098963 cites W1981669571 @default.
• W2894098963 cites W1982517701 @default.
• W2894098963 cites W1996377957 @default.
• W2894098963 cites W2000066194 @default.
• W2894098963 cites W2005632179 @default.
• W2894098963 cites W2030040211 @default.
• W2894098963 cites W2055737918 @default.
• W2894098963 cites W2061328414 @default.
• W2894098963 cites W2078651432 @default.
• W2894098963 cites W2093413285 @default.
• W2894098963 cites W2115314032 @default.
• W2894098963 cites W2117409056 @default.
• W2894098963 cites W2131897440 @default.
• W2894098963 cites W2134645587 @default.
• W2894098963 cites W2137583204 @default.
• W2894098963 cites W2146515240 @default.
• W2894098963 cites W2148488439 @default.
• W2894098963 cites W2148809544 @default.
• W2894098963 cites W2167743900 @default.
• W2894098963 cites W2313938220 @default.
• W2894098963 cites W2915747124 @default.
• W2894098963 doi "https://doi.org/10.1111/jcpt.12762" @default.
• W2894098963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30243033" @default.
• W2894098963 hasPublicationYear "2018" @default.
• W2894098963 type Work @default.
• W2894098963 sameAs 2894098963 @default.
• W2894098963 citedByCount "28" @default.
• W2894098963 countsByYear W28940989632019 @default.
• W2894098963 countsByYear W28940989632020 @default.
• W2894098963 countsByYear W28940989632021 @default.
• W2894098963 countsByYear W28940989632022 @default.
• W2894098963 countsByYear W28940989632023 @default.
• W2894098963 crossrefType "journal-article" @default.
• W2894098963 hasAuthorship W2894098963A5004277197 @default.
• W2894098963 hasAuthorship W2894098963A5011456672 @default.
• W2894098963 hasAuthorship W2894098963A5030817312 @default.
• W2894098963 hasAuthorship W2894098963A5082469456 @default.
• W2894098963 hasAuthorship W2894098963A5086570504 @default.
• W2894098963 hasBestOaLocation W28940989631 @default.
• W2894098963 hasConcept C119060515 @default.
• W2894098963 hasConcept C120665830 @default.
• W2894098963 hasConcept C121332964 @default.
• W2894098963 hasConcept C126322002 @default.
• W2894098963 hasConcept C156957248 @default.
• W2894098963 hasConcept C167135981 @default.
• W2894098963 hasConcept C2776376669 @default.
• W2894098963 hasConcept C2778980435 @default.
• W2894098963 hasConcept C2779489039 @default.
• W2894098963 hasConcept C2781414143 @default.
• W2894098963 hasConcept C2908647359 @default.
• W2894098963 hasConcept C44249647 @default.
• W2894098963 hasConcept C523546767 @default.
• W2894098963 hasConcept C54355233 @default.
• W2894098963 hasConcept C61511704 @default.
• W2894098963 hasConcept C71924100 @default.
• W2894098963 hasConcept C86803240 @default.
• W2894098963 hasConcept C99454951 @default.
• W2894098963 hasConceptScore W2894098963C119060515 @default.
• W2894098963 hasConceptScore W2894098963C120665830 @default.
• W2894098963 hasConceptScore W2894098963C121332964 @default.
• W2894098963 hasConceptScore W2894098963C126322002 @default.
• W2894098963 hasConceptScore W2894098963C156957248 @default.
• W2894098963 hasConceptScore W2894098963C167135981 @default.
• W2894098963 hasConceptScore W2894098963C2776376669 @default.
• W2894098963 hasConceptScore W2894098963C2778980435 @default.
• W2894098963 hasConceptScore W2894098963C2779489039 @default.
• W2894098963 hasConceptScore W2894098963C2781414143 @default.
• W2894098963 hasConceptScore W2894098963C2908647359 @default.
• W2894098963 hasConceptScore W2894098963C44249647 @default.
• W2894098963 hasConceptScore W2894098963C523546767 @default.
• W2894098963 hasConceptScore W2894098963C54355233 @default.
• W2894098963 hasConceptScore W2894098963C61511704 @default.
• W2894098963 hasConceptScore W2894098963C71924100 @default.
• W2894098963 hasConceptScore W2894098963C86803240 @default.
• W2894098963 hasConceptScore W2894098963C99454951 @default.
• W2894098963 hasFunder F4320311649 @default.
• W2894098963 hasFunder F4320322120 @default.
• W2894098963 hasIssue "1" @default.
• W2894098963 hasLocation W28940989631 @default.
• W2894098963 hasLocation W28940989632 @default.
• W2894098963 hasOpenAccess W2894098963 @default.
• W2894098963 hasPrimaryLocation W28940989631 @default.
• W2894098963 hasRelatedWork W1968674056 @default.
• W2894098963 hasRelatedWork W1980096466 @default.
• W2894098963 hasRelatedWork W2052849970 @default.
• W2894098963 hasRelatedWork W2061387038 @default.
• W2894098963 hasRelatedWork W2076929529 @default.
• W2894098963 hasRelatedWork W2325084897 @default.

• next